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Abstract
The majority of the heritability of coronary artery disease (CAD) remains unexplained, despite recent successes of genome-
wide association studies (GWAS) in identifying novel susceptibility loci. Integrating functional genomic data from a variety
of sources with a large-scale meta-analysis of CAD GWAS may facilitate the identification of novel biological processes and
genes involved in CAD, as well as clarify the causal relationships of established processes. Towards this end, we integrated
14 GWAS from the CARDIoGRAM Consortium and two additional GWAS from the Ottawa Heart Institute (25,491 cases and
66,819 controls) with 1) genetics of gene expression studies of CAD-relevant tissues in humans, 2) metabolic and signaling
pathways from public databases, and 3) data-driven, tissue-specific gene networks from a multitude of human and mouse
experiments. We not only detected CAD-associated gene networks of lipid metabolism, coagulation, immunity, and
additional networks with no clear functional annotation, but also revealed key driver genes for each CAD network based on
the topology of the gene regulatory networks. In particular, we found a gene network involved in antigen processing to be
strongly associated with CAD. The key driver genes of this network included glyoxalase I (GLO1) and peptidylprolyl
isomerase I (PPIL1), which we verified as regulatory by siRNA experiments in human aortic endothelial cells. Our results
suggest genetic influences on a diverse set of both known and novel biological processes that contribute to CAD risk. The
key driver genes for these networks highlight potential novel targets for further mechanistic studies and therapeutic
interventions.
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Introduction
Coronary artery disease (CAD) remains a leading cause of death
worldwide despite a variety of available interventions to reduce
cardiovascular events. CAD is partly familial [1,2], which
motivates genetic studies to elucidate novel pharmacological
targets. However, large-scale genome-wide association studies
(GWAS) have revealed a complex genetic architecture of CAD
susceptibility with modest effect sizes for the single nucleotide
polymorphisms (SNPs) detected to date [3,4]. The heritability
explained by the top SNPs is approximately 10%, whereas the
estimates of total heritability from family studies are substantially
higher, between 30% and 50% [1,2]. Furthermore, the SNP
associations themselves rarely provide evidence on their down-
stream functional consequences, which has prompted the need to
integrate DNA variants with functional data to better understand
the pathogenic processes.
Genes and their downstream products comprise a complex
regulatory machinery that sustains the delicate homeostasis of an
organism in a changing environment [5]. Genetic variants can
perturb parts of this regulatory network and its ability to restore
and maintain homeostasis in the presence of environmental
pressure. Consequently, the dysregulated biological processes such
as cholesterol metabolism and transport can eventually lead to
CAD [6]. To elucidate additional as yet unidentified CAD-related
processes, regulatory and functional data on the intermediate
tissue-specific molecular phenotypes are essential [7–9]. Regula-
tory networks between genes can be captured by various network
reconstruction algorithms [10–13]; functional information of
genetic variants can be derived from expression quantitative trait
loci (eQTLs; contain expression SNPs or eSNPs) that inform on
the downstream target genes of genetic variants [8,14–16].
Integration of these empirical data allows us to aggregate eSNPs
from multiple interacting genes into eSNP sets that collectively
perturb a part of the regulatory network. Subsequently, the eSNP
sets can be directly compared with SNP-to-disease associations
from a GWAS to connect gene networks to disease.
In this study, we apply an integrative genomics framework
(illustrated in Figure 1) to identify the genetically perturbed
regulatory networks that contribute to CAD. We make use of four
distinct types of data sources. First, associations between SNPs and
CAD were determined in 16 independent GWAS – 14 from the
CARDIoGRAM Consortium and two from the Ottawa Heart
Institute [4,17]. Second, the effects of SNPs on gene regulation
were determined according to eQTLs in multiple tissue-specific
genetics of gene expression studies of CAD-related tissues or cell
types in humans. As a result, we were able to link the CAD SNPs
from the GWAS with their empirically defined target genes.
Third, we downloaded known metabolic and signaling pathways
(in the form of gene sets) from public repositories, and
complemented these known pathways with data-driven network
modules of co-expressed genes from multiple transcriptomic
studies, to investigate the collective genetic risk via multiple
functionally related genes. Finally, we overlaid the identified CAD-
associated gene sets onto causal network models of gene-gene
interactions from multiple genomic studies to pinpoint the most
central regulatory genes. This combination of human genetics,
functional genomics, tissue-specific gene networks from empirical
data, and biological knowledge in this integrative genomics
framework provides us with further insights into the known and
hitherto unknown pathogenic processes that are relevant for CAD.
Results
SNP set enrichment analysis (SSEA) of canonical
pathways
Our first aim was to test if any of the known biological pathways
curated in Reactome, Biocarta and Kyoto Encyclopedia of Genes
and Genomes (KEGG) databases [18,19] was more likely to
harbor tissue-specific eSNPs that were also associated with CAD in
GWAS (Figure 1A). To reduce false discovery and identify the
most robust signals, we implemented a multi-stage design that
utilized two independent sets of CAD meta-analysis (Stage 1 and
Stage 2) each involving distinct sets of CAD cohorts, as well as the
overall meta-analysis of all 16 CAD cohorts (combined Stage 1+2
set; see Methods for details). The QQ plots of these three sets of
meta-analysis are shown in Figure S1. As majority of the cohorts
were from the CARDIoGRAM consortium, the GWAS results
from our new meta-analysis closely resembled those of CARDIo-
GRAM reported previously [4] and there were no new loci
identified at genome-wide significance level (Table S1). Tissue-
specific eSNPs from CAD related human cells or tissues including
adipose tissue, liver, human aortic endothelial cells (HAECs),
blood, as well as a pooled eSNP set from multiple tissues and cell
types (denoted as ‘All eSNPs’), were used for eSNP-to-gene
mapping, yielding five sets of eSNPs mapped to each pathway
(Materials and Methods). Each eSNP set representing a pathway
was then compared with random eSNP sets drawn from the
background eSNPs of matching tissue to look for enrichment of
low p value associations with CAD in GWAS using SSEA.
Enrichment was measured by a score calculated as the mean -log
P-value from Kolmogorov-Smirnov test and Fisher’s exact test (see
Methods) in SSEA. We defined a pathway to be significantly
associated with CAD when permutation-based false discovery
rates (FDRs) from Stage 1, Stage 2, and combined Stage 1+2
analyses simultaneously reached 20%, 20%, and 5%. Considering
that Stage 1 and Stage 2 GWAS datasets were independent, the
Integrative Genomics of Coronary Artery Disease
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,5% (20% * 20%=4%). An additional requirement for FDR,
5% from the combined Stage 1+2 analysis further ensured low
FDR.
To test whether our method can pick up true positive signals, we
selected two predefined CAD gene sets based on the GWAS
Catalog [20] and CADgene database [21] (details in Methods) as
positive controls. These positive controls exhibited strong and
consistent signals across multiple sets of SSEA using eSNPs from
individual tissues (7,score,29; equivalent to 1e-7,p,1e-29),
supporting the sensitivity of our approach. A total of 79 out of
833 canonical pathways tested were associated with CAD in at
least one of the five sets of SSEA using different eSNP sets
(Table 1; full results in Table S2). Among these, the lipid and
lipoprotein pathway from Reactome was significant in adipose
eSNP analyses (score 9.8). On the other hand, the bile acid
recycling pathway was strongly indicated by the liver eSNPs
(score 8.5). The next large group of CAD-associated pathways
was related to the immune system: ‘Immunoregulation with
lymphoid and non-lymphoid cells’ was the top Reactome
pathway (score 11.4 for adipose eSNPs), ‘Antigen processing
and presentation’ from KEGG was significant in the liver (score
10.8), and ‘Adhesion and diapedesis of granulocytes’ from
Biocarta was a significant pathway when using the HAEC eSNPs
(score 3.7). A number of pathways that were directly related to
the vascular system or heart, and four pathways that were related
to blood coagulation were also associated with CAD. For
instance, the SSEA implicated the vascular endothelial growth
factor (VEGF), hypoxia and angiogenesis pathway, and the
platelet/endothelial cell adhesion molecule 1 (PECAM1) path-
way. In essence, the analysis of the curated pathways was able to
detect genetic links between CAD and its classical risk factor
dyslipidemia, and other suspected CAD processes such as
inflammation and vascular dysfunction. More importantly, the
use of tissue-specific eSNPs sets helped implicate the most
relevant tissues for the significant pathways.
Our analyses also revealed pathways that so far have not been
clearly implicated in CAD development. These included four
pathways related to the nervous system (such as ‘Erythropoietin
mediated neuroprotection through NF-kB’ and ‘TrkA receptor
signaling pathway’ from BioCarta), 13 cell cycle and proliferation
pathways (such as ‘NRAGE signals death through JNK’ from
Reactome and ‘EGF signaling’ from BioCarta), and ten DNA or
RNA pathways (such as ‘Spliceosome’ from KEGG and ‘E2F
regulation of DNA replication’ from Reactome). Furthermore, we
observed pathways such as ‘Phase I functionalization’ from
Reactome and ‘Proteasome’ from KEGG that have a role in the
disposal and neutralization of harmful molecules. Pathways that
covered amino acids and peroxisome proliferator-activated
receptors were also among the significant signals.
We compared the top knowledge-driven pathways detected with
our eSNP-based SSEA to those detected by several widely used
location-based gene-to-SNP mapping methods for gene set
enrichment analysis including iGSEA4GWAS [22], MAGENTA
[23] and GSA-SNP [24], and observed considerable variation in
the results between methods, with relatively greater consistency
between our SSEA approach and iGSEA4GWAS (data not
shown). The results from iGSEA4GWAS are reported in a
separate manuscript by Ghosh et al (under review). We found that
signals from SSEA such as lipid metabolism, immune and
inflammatory pathways, PDGF signaling, NOTCH signaling,
and PPAR signaling could be replicated in one or more of the
other methods tested. Nonetheless, SSEA and iGSEA4GWAS
each yielded additional biologically plausible pathways.
Our current analysis included majority of the large-scale CAD-
related eQTL sets published before mid 2013. During the revision
of this manuscript, several additional blood eQTLs became
available [25–27]. We tested the pathways identified in our study
using the updated blood eQTLs and found minimal impact on our
main results, with Pearson correlation coefficient of the pathway
scores being 0.96 (comparison between scores before and after
incorporating the new blood eQTLs is shown in Table S3).
SSEA of co-expression modules and formation of non-
overlapping supersets
To uncover hitherto unknown biological processes, we aug-
mented the set of canonical pathways with data-driven co-
expression modules (empirical sets of tightly co-regulated genes)
from multiple previous human and mouse studies (detailed in
Materials and Methods). A total of 341 of the 2,706 modules tested
satisfied the FDR,20% in both Stage 1 and Stage 2, and FDR,
5% in the combined meta-analysis (Table S4). Given that
canonical pathways defined by different databases may overlap
and also co-expression modules may overlap with known
biological pathways, we collected all CAD-associated gene sets
regardless of their source (79 canonical pathways + 341 co-
expression modules=420 in total), and analyzed their overlap
structure (Figure 1B; overlap matrix in Figure S2). After merging
CAD gene sets with overlap of .20% in their member genes
(details in Materials and Methods), 62 non-overlapping merged
supersets remained.
To ensure the merged supersets still captured the features of the
significant pathways, we performed a second round of SSEA on
the supersets and applied a stringent Bonferroni-corrected
statistical cutoff (correcting for the total number of pre-merged
gene sets, n=3539, not 62 supersets) to focus on the most reliable
signals. Therefore, although the second round of SSEA was mainly
confirmatory to ensure that we did not lose the signals during
merging/trimming, a highly stringent Bonferroni-correction that
considered multiple testing of 3539 original gene sets (not 62
Author Summary
Sudden death due to heart attack ranks among the top
causes of death in the world, and family studies have
shown that genetics has a substantial effect on heart
disease risk. Recent studies suggest that multiple genetic
factors each with modest effects are necessary for the
development of CAD, but the genes and molecular
processes involved remain poorly understood. We con-
ducted an integrative genomics study where we used the
information of gene-gene interactions to capture groups
of genes that are most likely to increase heart disease risk.
We not only confirmed the importance of several known
CAD risk processes such as the metabolism and transport
of cholesterol, immune response, and blood coagulation,
but also revealed many novel processes such as neuro-
protection, cell cycle, and proteolysis that were not
previously implicated in CAD. In particular, we highlight
several genes such as GLO1 with key regulatory roles
within these processes not detected by the first wave of
genetic analyses. These results highlight the value of
integrating population genetic data with diverse resources
that functionally annotate the human genome. Such
integration facilitates the identification of novel molecular
processes involved in the pathogenesis of CAD as well as
potential novel targets for the development of efficacious
therapeutic interventions.
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threshold were truly robust. Note that this level of Bonferroni
correction is highly conservative because we are treating all 3539
gene sets as independent. In reality, the highly overlapping
structures among these gene sets make the number of truly
independent gene sets much smaller.
Out of the 62 non-overlapping supersets, 22 were confirmed to
be genetically associated with CAD in the second round of SSEA
(Table S5) and the top six supersets are summarized in Table 2.
The data-driven supersets implicated lipid metabolism (‘Lipid I’
and ‘Lipid II’), the immune system (‘Immunity’ and ‘Antigen’) and
coagulation processes (‘Lipid II’), consistent with the findings from
the canonical pathways. Eight supersets did not significantly
overlap with any known pathway or process and could not
therefore be annotated by functional categories (hence named
‘‘Unknown’’; Table S5).
Key driver analysis (KDA) of CAD-associated gene
supersets
In order to determine the regulatory genes (referred to as key
drivers) at the center of the CAD-associated supersets as a means
to further explore regulatory mechanisms and prioritize disease
genes, we performed KDA using tissue-specific Bayesian network
models constructed from transcriptomic and genetic datasets from
multiple human and mouse studies (Figure 1C; details in Materials
and Methods) [12,28,29]. The topology of these Bayesian
Figure 1. Schematic overview of the study design. A) The SNP set enrichment analysis (SSEA) comprised four steps. First, gene sets from
knowledge-driven pathways and data-driven co-expression modules were collected. Second, the gene sets were converted to expression SNP (eSNP)
sets according to genetics of gene expression or eQTL studies. Third, P-values from CAD GWAS were extracted for each eSNP. Fourth, the GWAS P-
values within eSNP sets were compared against random expectation to derive pathways and network modules enriched for CAD genetic signals. B)
Overlapping CAD-associated gene sets were merged and trimmed into non-overlapping supersets. C) Integration of Bayesian gene-gene network
models with CAD-associated supersets to determine key driver genes based on network topology.
doi:10.1371/journal.pgen.1004502.g001
Integrative Genomics of Coronary Artery Disease
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can help infer key network drivers. The KDA results for the top six
supersets are summarized in Table 3 and full list of key drivers are
in Table S6. To test if the key driver genes were also responsible
for the enrichment of CAD genetic signals in each of the CAD
superset, we also ranked and selected the member genes whose
eSNPs (i.e., SNPs that are associated with the expression levels of
the member genes) showed the strongest CAD association within
the superset, termed ‘‘GWAS signal genes’’, for comparison
(Table 3). Interestingly, the key driver genes were mostly different
from the GWAS signal genes, which supports a previously
observed phenomenon [30] that important regulatory genes may
not harbor common susceptibility polymorphisms by natural
selection and, conversely, that a majority of common disease
susceptibility loci (as captured by GWAS) do not involve key
regulatory genes but are situated in the periphery of biological
networks.
Both the ‘Lipid I’ and ‘Lipid II’ supersets fell under the general
category of lipid and fatty acid metabolism (Figure 2A and 2B).
They share 14% of their members, including seven apolipopro-
teins, but were considered non-overlapping according to our a
priori overlap threshold of 20%. In fact, the key drivers for ‘Lipid
Table 1. Knowledge-based grouping of canonical pathways that were significantly enriched for CAD genetic loci.
Category Selected pathways All eSNPs Adipose Liver Blood HAEC
Control GWAS Catalog 29.0* 9.0* 25.1* 17.2* 7.3*
CADGene 12.0* 11.9* 9.1* 1.3 1.7
Lipids (9) Metabolism of lipids and
lipoproteins (Reactome)
10.0* 9.8* 2.4 0.7 1.0
Fatty acid metabolism (KEGG) 5.2* 10.3* 1.6 0.4 0.7
Recycling of bile acids and
salts (Reactome)
5.3* - 8.5* - -
Immune system (24) Immunoregulation between
lymphoid and other cells (Reactome)
9.4* 11.4* 8.6* 1.8 1.6
Antigen processing and presentation
(KEGG)
8.9* 8.1* 10.8* 2.9* 3.0
Th1/Th2 differentiation (Biocarta) 6.6* 5.1* 5.3* 2.0 0.2
Adhesion and diapesis of lymphocytes
(Biocarta)
3.3 6.0* - 0.8 3.6*
Adhesion and diapedesis of
granulocytes (Biocarta)
3.3 3.8* - 0.9 3.7*
Cellular stress response (6) VEGF, hypoxia and angiogenesis
(Biocarta)
4.5* 7.7* 5.9* 3.2 1.4
Erythropoietin mediated
neuroprotection through
NF-kB (Biocarta)
3.0* 4.8* 4.6* 2.2 2.6
Hypoxia-inducible factor in the
cardiovascular system (Biocarta)
1.5 3.8* 2.6 1.9 1.1
Cell cycle and growth (18) Notch-HLH transcription (Reactome) 2.5 3.3* - - 0.6
NRAGE signals death through JNK
(Reactome)
3.2* 3.7* 2.5 5.3* 0.5
EGF signaling pathway (Biocarta) 1.7 2.7* 1.7 1.8 1.2
G1/S transition (Reactome) 1.2 0.6 5.3* 0.1 0.2
DNA and RNA (7) Double-strand break repair
(Reactome)
3.1* 2.5 2.3 3.3* 0.7
Spliceosome (KEGG) 1.7 0.6 0.3 5.9* 0.5
Protein metabolism (6) Metabolism of proteins
(Reactome)
2.1* 4.2* 1.1 2.6 1.5
Proteasome (KEGG) 0.9 0.3 3.6* 0.2 0.7
Post-translational protein
modifications (Reactome)
1.3 3.6* 2.3 0.7 1.5
Other (6) Bioactive peptide induced
signaling (Biocarta)
3.2* 5.9* 0.3 1.5 0.2
PPAR signaling pathway (KEGG) 3.1* 5.9* 0.6 0.6 0.7
Glycine, serine and threonine
metabolism (KEGG)
2.4* 2.2* 1.3 2.4 3.4
The enrichment score was defined as the mean of negative log-transformed Kolmogorov-Smirnov and Fisher P-values for over-representation of high-ranking GWAS
SNPs among the eSNPs that affect the expression of the pathway member genes. The number in parentheses in the first column indicates the number of CAD-
associated pathways (detailed in Table S1).
*FDR,20% in Stage 1 and 2 respectively, and FDR,5% in combined Stage 1 & 2.
doi:10.1371/journal.pgen.1004502.t001
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ETFDH and EHHADH) and cholesterol biosynthesis (SQLE),
whereas ‘Lipid II’ was regulated by coagulation (PLG and
HRG) and carrier proteins (GC and PZP), which confirms non-
overlapping functionality between the two supersets. Of note,
two critical genes involved in lipoprotein metabolism, LPL
and LDLR,w e r ea m o n gt h et o pG W A Ss i g n a l sg e n e sf o r
‘Lipid I’.
Two supersets of immune system genes – ‘Antigen’ and
‘Immunity’ - were significantly enriched for CAD loci in adipose
tissue and the liver (Figure 2D and 2E). The ‘Antigen’ superset
owes its annotation to the human leukocyte antigen (HLA) and
mouse HLA orthologs (H2 genes) that comprise 21 of the 221
member genes. We found the key drivers for this superset such as
GLO1, PPIL1 and DECR2 to be highly consistent across
Bayesian networks from multiple tissues (Table S7). The ‘Immu-
nity’ superset contains a variety of immune response genes
including six HLA genes and 18 cytokines or their receptors such
as CCL2, CD antigen genes, CXCL10, IL2RB and TLR2. Four of
the top five key drivers for the ‘Immunity’ superset (PTPRC, FYB,
FCGR1A and FCER1G) participate in the immune response, and
three (PTPRC, FYB and FCER1G) have been previously
identified as key drivers of an inflammatory gene signature
underlying multiple diseases (including CAD) [12].
We could not annotate two out of our six top supersets
(‘Unknown I’ and ‘Unknown II’). These supersets, however, have
consistent network key drivers across multiple tissues (Figure 2C
and 2F, Table S7). ‘Unknown I’ contained a diverse set of key
driver genes such as SGK1, SIK1 and SLC10A6 (sodium
metabolism and hypertension), MT2A and TSC22D3 (glucocor-
ticoid signaling), GADD45G, ERRFI1, GPRC5A,a n dEGFR
(cell growth and apoptosis), and CEBPB, CEBPD,a n dKCNA5
(heart development and function). Possible functions of ‘Un-
known II’ include RNA metabolism (ZC3H7B), protein methyl-
ation (PRMT1), glycosylation (ALG8), chaperone recycling
(DNAJC7) and ubiquitination (UBE2S), and similar annotations
could also be found for the network neighboring genes of these
key drivers. Of note, the gene CYP39A1 which converts
cholesterol into bile acid was shared between ‘Lipid I’, ‘Antigen’
and ‘Unknown II’ supersets.
Table 2. CAD enrichment scores for selected non-overlapping supersets after the merging of CAD-associated canonical pathways
and co-expression modules.
Superset Overlap with known processes All eSNPs Adipose Liver Blood HAEC
Lipid I Lipid, fatty acid and steroid metabolism;
oxidoreductase; PPAR signaling;
mitochondrial beta-oxidation;
branched-chain amino acid degradation;
cholesterol biosynthesis; unsaturated
fatty acid biosynthesis
5.4* 9.4* 0.4 0.4 0.7
Lipid II Lipid, fatty acid and steroid metabolism;
oxidoreductase; vesicles; xenobiotics;
complement and coagulation system
10.3* 11.0* 1.9 1.8 0.1
Antigen Human leukocyte antigens; bone
reabsorption
10.3* 9.5* 8.6* 3.7 1.1
Immunity Wound and inflammatory
responses; cell activation
6.1* 7.4* 8.7* 1.5 1.4
Unknown I - 3.5 7.4* 4.4 1.2 0.2
Unknown II - 2.9 6.4* 3.9 2.2 0.2
The enrichment score was defined as the mean of negative log-transformed Kolmogorov-Smirnov and Fisher P-values for over-representation of high-ranking GWAS
SNPs among the eSNPs that affect the expression of the superset member genes.
*P,0.05 in either Fisher’s exact test or Kolmogorov-Smirnov test after Bonferroni correction for the 3,539 original gene sets.
doi:10.1371/journal.pgen.1004502.t002
Table 3. Top five genes whose eSNPs show strongest association with CAD in GWAS (termed ‘‘GWAS signal genes’’) and key driver
genes for selected CAD-associated supersets.
Superset GWAS signal genes* Key driver genes
#
Lipid I SREBF1, LPL, LDLR, CYP4A11, ME1 DCI, SQLE, ETHDH, SLC22A5, EHHADH
Lipid II TMEM116, TMEM27, MAT1A, LRRC19, NAT2 GC, CES3, PZP, HGR, PLG
Immunity CTSS, HLA-B, OAS1, HLA-DRB1, HLA-DQB1 PTPRC, NCKAP1L, FCGR1A, FYB, FCER1G
Antigen CD2AP, AS3MT, HCG4, TAF11, FLOT1 VPS52, PPIL1, GLO1, GFER, DECR2
Unknown I NT5C2, SURF6, ARL3, LMO4, TIE1 DNAJC7, UBE2S, ALG8, ZC3H7B, PRMT1
Unknown II ALS2CR13, TMEM116, C10orf26, CEACAM3, NM_152451 CEBPD, SGK1, SLC10A6, KCNA5, MAP3K6
*Genes within superset whose eSNPs (i.e. putative functional SNPs that affect gene expression) show best association with CAD in the GWAS meta-analysis.
#The key driver genes were ascertained by combining key driver analyses of all available Bayesian networks, and taking into account both the consistency across
datasets and the KDA statistics.
doi:10.1371/journal.pgen.1004502.t003
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scoring superset
The ‘Antigen’ superset had the highest combined CAD
association score across the five sets of SSEA using eSNP sets
from different tissues (Table 2) and their key driver genes identified
were highly consistent across the Bayesian networks used for KDA
(Table S7). For these reasons, we tested the effects of silencing
three of the key drivers, glyoxalase I (GLO1), peptidylprolyl
isomerase I (PPIL1) and peroxisomal 2,4-dienoyl CoA reductase 2
(DECR2), on the expression of member genes in the ‘Antigen’
superset in HAECs, aiming to validate the role of these key drivers
in regulating this CAD superset. HAECs were chosen based on
their critical role in maintaining a healthy vessel wall and
knowledge that endothelial dysfunction is observed early in the
development of atherosclerosis [31]. Of note, the number of
HAEC specific eSNPs was relatively low due to the limited sample
size in the original study [32], which could explain the lack of
significant pathway enrichment signals in this cell type in this
study. However, this statistical power issue should not be
misconstrued as a lack of relevance of this cell type in the
pathogenesis of CAD.
ThreeseparatesiRNAsagainsttheGLO1transcript NM_006708
(Qiagen Catalog Numbers SI04175892, SI04206244, SI04266052)
resulted in 86%, 88% and 91% reduction in GLO1 expression, and
siRNA SI04284224 against the PPIL1 transcript NM_016059
resulted in 87% reduction. DECR2 expression level was too low
in HAECs to be informative. Whole genome transcript
expression in response to GLO1 and PPIL1 suppression was
measured using microarrays and then compared with that from
scrambled siRNAs (null control) to detect genes with significant
changes.
A total of 485 and 656 genes were affected by GLO1 and
PPIL1 suppression, respectively (P,0.001 for both). Due to
substantial overlap (281 genes were affected by both GLO1 and
PPIL1), we pooled the 860 unique genes that were significantly
affected by either GLO1 or PPIL1. We determined how many of
these top genes were neighbors by two edges to any of the five key
drivers (GLO1, PPIL1, DECR2, VPS52 and GFER) of the
‘Antigen’ superset when considering all available Bayesian
networks. We found the 547 neighbor genes to be enriched for
the differentially expressed genes by 1.7 fold (37 observed vs. 21.5
expected, P=5.5610
24 by Fisher’s exact test), indicating that the
suppression of GLO1 and PPIL1 perturbed the ‘Antigen’ superset
in HAEC.
To verify the connection of GLO1 and PPIL1 perturbations to
CAD, we tested the two pre-defined CAD positive control gene
sets (Table 1) against the differential P-values from the siRNA
experiments. The CADgene positive control set was significantly
associated with altered expression due to either GLO1 (PFisher,
0.0001, PK-S=0.0042) or PPIL1 suppression (PFisher,0.0001,
Figure 2. Key driver genes of six CAD-associated supersets, and their adjacent regulatory partners. Key driver genes were denoted as
larger nodes in the network. Genes were colored based on their membership in the six CAD-associated supersets. A) ‘Lipid II’ superset in red. B) ‘Lipid
I’ superset in yellow. C) ‘Unknow II’ superset in lime. D) ‘Immunity’ superset in green. E) ‘Antigen’ superset in blue. F) ‘Unknown I’ superset in magenta.
Only edges that were present in at least two Bayesian networks constructed from independent studies were included.
doi:10.1371/journal.pgen.1004502.g002
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genes from CAD-related processes are significantly more affected
by GLO1 and PPIL1 knockdown compared to a random set of
genes in HAEC.
Discussion
We performed an integrative genomics study that combined
association signals from a large GWAS, tissue-specific eQTL
datasets, known canonical pathways, and data-driven regulatory
networks to gain insights into the causal molecular mechanisms of
CAD. Our approach identified both established and novel
biological processes supported by functional evidence; specifically,
the expression levels of the member genes within these processes
were controlled by multiple CAD-associated SNPs. To dissect the
key regulatory mechanisms, we derived a network representation
of the central genes involved in the pathogenic processes and
investigated how the affected genes were related to known
biological pathways and metabolic cascades and how the processes
were inter-connected in multi-tissue regulatory networks. Our
study revealed a highly complex and multifactorial genetic basis
for CAD, and implicated several known and novel causal
pathways along with their potential regulators deserving of further
study.
Several aspects of this study distinguish it from previous
pathway and network studies of CAD. First, we used data from
eQTL studies of CAD-related tissues or primary cell types to
assign eSNPs to genes, whereas previous approaches have
primarily utilized genomic location for assignment of SNPs to
genes [3,22,23,33,34]. Our method incorporates empirical func-
tional support and tissue specificity into the analyses to increase
the sensitivity of detecting tissue-specific molecular events that
would have been missed by conventional methods [22,23,33] and
to enhance the biological and mechanistic interpretability of the
disease-related signals [9,35–37]. Our partial re-analysis of data
incorporating recently reported blood eSNPs suggests that the
addition of new eQTLs reinforces the significance of the pathways
identified thus far. Second, we tested both knowledge-driven and
data-driven gene sets to expand the coverage of novel biological
processes. Third, we used two large independent CAD GWAS
meta-analyses, merged and trimmed overlapping CAD-associated
gene sets, and imposed a strict Bonferroni threshold for final
statistical evaluation of the CAD signals to avoid false positives and
focus on the most reliable core processes for CAD. Fourth, we
utilized scores of empirically-derived gene networks from diverse
CAD-related tissues to extract the CAD network architecture and
the key driver genes, whereas previous studies have relied on
literature-based topologies, protein-protein interaction networks,
or single-tissue networks [3,38–40]. Lastly, we performed targeted
siRNA studies in HAEC to provide experimental support for our
in silico findings.
Of note, the KDA approach we utilized has been recently
demonstrated by multiple studies to have the capacity to identify
hidden novel regulatory genes that are missed by traditional
analysis, and novel predictions from each of these studies have
been experimentally validated [12,28,41]. The key drivers
identified, however, are not necessarily GWAS hits. In contrast,
it is their downstream or peripheral genes that are more likely to
be identified in GWAS and the expression of these genes are more
likely to be cis-regulated by GWAS SNPs. This may explain why a
majority of the GWAS hits uncovered to date only have small
effects on complex disease phenotype. As elucidated previously by
Goh et al. [30], the lack of GWAS signals from key driver genes
can be explained by evolutionary constraints imposed on
important regulators because strong genetic perturbations in these
key regulators are more likely to be deleterious. If certain genetic
polymorphisms within key regulatory genes (e.g., transcription
factors) indeed successfully segregate in general population and
can be identified in GWAS, these polymorphisms tend to be cis-
eSNPs of the regulators themselves and then trans-eSNPs of
additional disease genes [25].
Our results support the role of genetic perturbation to lipid
metabolism, immune response and inflammation, coagulation,
and vascular wall function in the etiology of CAD. Apart from
cholesterol metabolism and transport, a causal role for many of
these processes in pathogenesis of CAD has been debated for
years. For instance, recent Mendelian randomization studies as
well as randomized control trials of cardiovascular drugs have
demonstrated that a number of known key genes within these
pathways (e.g. CRP, fibrinogens) are not causally associated with
CAD [42–44]. Our results suggest that a critical mass of causal
variants may be inherited within many of the genes in these
pathways even if the pathway includes some genes that have no
causal role in the pathogenesis of CAD.
We identified novel biological processes such as neuroprotec-
tion, cell cycle and proteolysis that were perturbed by the CAD-
associated genetic variants. Furthermore, the data-driven network
models identified CAD-associated gene sets that did not overlap
with any known biological processes. We merged the knowledge-
based biological pathways and data-driven functional units of
genes derived from expression patterns to bridge the knowledge
gaps, and focused on six gene sets that were not only strongly
associated with CAD in human GWAS but also exhibited a
consistent causal network topology around a limited number of
key regulatory genes.
The supersets ‘Lipid I’ and ‘Lipid II’ are involved in cholesterol
and lipid biosynthesis or degradation. The ‘Lipid II’ superset
appears to have more diversified functions beyond lipid biosyn-
thesis and transport, as it contains multiple additional genes from
coagulation and complement pathways. If ‘Lipid I’ and ‘Lipid II’
were simultaneously perturbed, one can speculate that the lipid
transport system would become overwhelmed, wound healing
processes and the complement cascade would become over-
activated, and the lipid-rich debris would feed the accumulation
of plaque on the vessel wall. Furthermore, two of the central
genes in Lipid II, plasminogen (PLG) and the histidine-rich
glycoprotein (HRG) regulate the fine balance between clotting
and fibrinolysis, which can affect the propensity of thrombosis
after plaque rupture.
The strongest overall CAD association was observed for the
‘Antigen’ superset. The key drivers were highly consistent
across tissues but, surprisingly, none of them have been directly
implicated in antigen processing. In fact, many of the network
driver genes appear to be involved in protein processing, and
endosomal and lysosomal functions. For instance, glyoxalase 1
(GLO1) plays a critical part in the enzymatic defense against
dysfunctional glycated forms of proteins [45], the vacuolar
protein sorting 52 homolog (VPS52) is involved in the
transport and sorting of proteins from the plasma membrane
to the lysosome via mannose-6-phosphate receptors [46], the
N-acetylglucosamine-1-phosphate transferase gamma subunit
(GNPTG, top 10 key driver, between GLO1 and GFER in
Figure 2) is part of mannose-6-phosphate synthesis [47], and
peptidylprolyl isomerase (PPIL1) is a member in the cyclo-
philin family that regulates protein folding and immune
responses [48]. Of note, there may also be a direct link to
lipid metabolism: the peroxisomal 2,4-dienoyl CoA reduc-
tase (DECR2), which participates in the beta-oxidation of
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GLO1 is an interesting candidate for a causal CAD gene.
Diabetes, kidney disease, and diabetic kidney disease in particular
increase the risk and severity of CAD dramatically [50,51], and
the glyoxalase system is an important protective mechanism
against the formation and subsequent accumulation of advanced
glycation end products that are believed to promote diabetic end-
organ damage. In a mouse study, a Glo1 knock-down model
spontaneously developed kidney disease even without diabetes
[52], and a single case of human GLO1 deficiency exhibited both
end-stage renal disease and severe atherosclerosis [53]. A recent
study demonstrated a protective role of Glo1 in restoring
neovascularization of ischemic tissue in diabetic rats [54]. In our
study, knock-down of GLO1 in HAECs perturbed the expression
of many of the same genes that were affected by CAD-associated
SNPs in the human GWAS. Therefore, the glyoxalase system may
represent one common pathway responsible for both the
microvascular and macrovascular complications observed in
subjects with diabetes.
The ‘Immunity’ superset may represent the same core
inflammatory signature that we have observed across species,
tissues, and multiple diseases [12]. Four of the top key drivers
(HCK, TYROBP, NCKAP1L and AIF1) identified from the
previous multi-disease inflammatory signature were also detected
as key drivers for the ‘Immunity’ superset in this study (Figure 2D).
Although we cannot provide definitive answers on the sequence of
events, one may hypothesize that the ‘Immunity’ superset executes
the downstream machinery that is recruited in response to the
antigen presentation in cells under metabolic stress.
The central genes in the ‘Unknown I’ superset include the
serum glucocorticoid regulated kinase 1 (SGK1), a mitogen-
activated protein kinase (MAP3K6), a sodium/bile acid co-
transporter (SLC10A6) and a C/EBP transcription factor
(CEBPD). Of these, SGK1 has been studied the most and is
believed to be important for renal sodium absorption, salt-
sensitivity to hypertension and glycemia, cardiac repolarization,
and numerous other processes [55]. MAP3K6 regulates VEGF
expression [56], and its expression was altered in a mouse model of
cardiomyopathy [57]. The SLC10 gene family contains three
sodium-dependent transporters, of which SLC10A6 transports
sulfoconjugated steroid hormones. One of the shared genes
between ‘Antigen’ and ‘Unknown I’ in Figure 2, salt-inducible
kinase 1 (SIK1), is thought to be part of the sodium-sensing
network [58]. Cyclin-dependent kinase inhibitors (CDKN) may be
causally related to atherosclerosis [3,59], although the exact role of
CDNK1A (adjacent to MAP3K6 and SLC10A6 in Figure 2)
remains unclear. Thus, the superset ‘Unknown I’ appears bring
together processes quite relevant to CAD including glucocorticoid
signaling, vascular stress response, cell growth, and blood pressure
control.
‘Unknown II’ could not be annotated by known processes and
the functions of the core genes remain poorly understood. There
were a number of genes that may regulate methylation, histones,
chromatin, and splicing (ING3, CBX6, LMNB1, SFRS5), post-
translational protein modifications and activation (PRMT1,
ALG8, PDIA3, DNAJC7), ubiquitination (UBE2S, RNF25,
RNF146), cytoskeleton organization (ARPC3, MAP1LC3A,
DYNLL2, ARL6IP5), and cell cycle (CD82, ING3, UBE2S,
MDFI, TRAF4). It is possible that the genes within ‘Unknown II’
participate in the stress-induced epigenetic and proteomic changes
that contribute to atherogenic processes. If this is true, it may
explain why the curated pathways, many of which consist of
chemical reactions between metabolites, missed the predominantly
regulatory gene networks such as ‘Unknown I’ and ‘Unknown II’.
We had a wealth of data sources at our disposal in this study to
derive a comprehensive view of the complex mechanisms of
CAD. Nevertheless, we acknowledge the following limitations.
First, our study cannot distinguish pathways or gene subnetworks
that are more relevant to specific subtypes of CAD from those
which cause CAD through more general mechanisms involving
relatively well-understood cardiometabolic processes. Future
studies involving sample sets that include more refined subtyping
of cases may help further advance our understanding in this
respect. Second, although the concept of eQTL as an empirical
alternative to the traditional location-based gene-SNP mapping
in pathway analysis is appealing from a biological perspective as it
carries functional implications and allows detection of tissue-
specific signals, in practice, however, the lack of comprehensive
and large enough genetics of gene expression studies may limit
the power and the biological coverage of the approach, as the
total number of eSNPs is typically lower and eSNPs from
additional CAD-related cell types of tissues are not necessarily
available. On the other hand, emerging resources such as
ENCODE [60,61] and GTEx [62] are likely to improve the
situation in the future.
In conclusion, we used an integrative genomics framework to
shed light on the key genes and regulatory processes involved in
the pathogenesis of CAD. We detected genetically driven
perturbations of several pathways with a strong a priori evidence
of involvement in CAD (cholesterol synthesis, inflammation, and
blood coagulation), as well as novel processes (neuroprotection,
epigenetic and post-translational modifications, intracellular trans-
port, proteolysis, and cell cycle). The data suggest that many genes
in these biological processes are causally associated with CAD
even if this may not be the case for all the pathway or network
members. We verified the importance of the key drivers in the top-
scoring gene set using an experimental gene expression model.
Thus, the CAD associated gene networks and key drivers
identified in this study warrant further validation in additional
population genetic and mechanistic studies. Further knowledge
gained through such studies has the potential to lead to major
advances in the development of therapeutic strategies to reduce
the risk of CAD.
Materials and Methods
Overall analysis flow
The overall integrative framework is depicted in Figure 1. First,
we applied a modified SNP set enrichment analysis (SSEA) [36,37]
to find sets of functionally related genes that were associated with
CAD (Figure 1A). In this analysis, we used knowledge-based
canonical pathways and data-driven co-expression network
modules as the functional units of genes that were tested for
CAD association, tissue-specific eQTL studies to connect the
genes to SNPs, and CAD GWAS to provide the associations
between SNPs and CAD. To reduce false discovery and identify
the most robust signals, we implemented a multi-stage design that
leveraged two independent GWAS meta-analyses of CAD. Next,
we investigated the statistically significant CAD-associated path-
ways and co-expression modules for shared genes, and merged any
overlapping gene sets into non-overlapping supersets (Figure 1B).
Lastly, the key regulator genes for each superset were determined
by integrating multiple tissue-specific Bayesian causal network
models of gene interactions with the CAD-associated gene
supersets (Figure 1C).
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The design, clinical classification and genotyping within the
Coronary ARtery DIsease Genome-wide Replication And Meta-
Analysis (CARDIoGRAM) Consortium have been described
previously [4,63]. The dataset used in this study comprised
25,491 cases with coronary artery disease, myocardial infarction or
both and 66,819 controls from the 14 cohorts within CARDIo-
GRAM and two GWAS by the Ottawa Heart Institute in
collaboration with Cleveland Clinic and Duke University [17].
The 16 GWAS were split into two independent sets (Table S8):
The Stage 1 set combined the results from the Ottawa Heart
Genomics Study with the Cleveland Clinic Gene Bank (OHGS_A
and OHGS_CCGB_B), the CAD component of the Wellcome
Trust Case Control Consortium (WTCCC), the Duke CATH-
GEN Study, and the German Myocardial Infarction Family
Studies I, II, III with Collaborative Health Research in the Region
of Augsburg (GerMIFS1, GerMIFS2, GerMIFS3/KORA). The
remaining CARDIoGRAM cohorts formed the Stage 2 set and
included Atherosclerotic Disease VAscular functioN and genetic
Epidemiology Study (ADVANCE), CADomics, Cohorts for Heart
and Aging Research in Genomic Epidemiology (CHARGE),
deCODE CAD, Ludwigshafen Risk and Cardiovascular Health
Study (LURIC/AtheroRemo 1, LURIC/AtheroRemo 2), Med-
Star, Myocardial Infarction Genetics Consortium (MIGen) and
the PennCath Study.
Genotyping of the individuals was performed by Affymetrix or
Illumina platforms and imputed to 2.5 million SNPs prior to meta-
analyses [4]. Ancestry was restricted to European origin by self-
reporting or principal component analysis of genotypes or both.
The Ottawa cohorts were imputed separately using IMPUTE2
and MACH software, and a reference panel that included 112
European genomes from the 1000 Genomes Project (August 2009)
and 298 additional subjects from a separate CEU/TSI reference
panel [17].
Correcting of population stratification was performed as
described previously [17]. The smartPCA (principal components
analysis) program from EIGENSOFT v3.0 [64] was used to
identify and remove subjects of admixed or non-European
ancestry. Study subjects were processed with 270 HapMap2
subjects for PCA (90 CEU, 90 JPT+CHB, 90 YRI). In the
resulting first 2 dimensions from PCA, k-means was used to
ascertain the center of each of the CEU, JPT+CHB, and YRI
clusters, and the original 2 PC dimensions were projected onto
these axes. Subjects were removed if they fell outside an oval
whose major axes were 10 times the standard deviation of the
CEU cluster along the 2 transformed axes.
The SNP-level associations were estimated by a meta-analysis
approach similar to that used for CARDIoGRAM [4]. SNPs with
minor allele frequency below 1%, significant Hardy-Weinberg
equilibrium (P,0.0001), imputation quality below 50% or call rate
below 75% were excluded. Rare SNPs that were present in less
than three Stage 1 GWAS or less than five Stage 2 GWAS were
also excluded. The GWAS were analyzed jointly by a fixed-effect
inverse-variance weighted model within the Stage 1 and Stage 2
sets, respectively. Heterogeneous SNPs with significant Q and I
statistics (P,0.0001) were analyzed by DerSimonian and Laird
inverse variance model of random effects. We also used all
available cohorts to create an overall meta-cohort (denoted as
Stage 1+2).
Knowledge-driven pathways
We included curated pathways from the Reactome, Biocarta
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
databases [18,19]. The Reactome database is based on reactions
between diverse molecular species rather than limiting the
pathways to protein-protein interactions or other types of non-
biological categories. Also, the nested structure of the Reactome
database helps to increase the coverage to multiple levels of gene
set organization. The KEGG database represents carefully curated
and experimentally validated pathways of metabolic processes and
gene sets of human diseases, while BioCarta is a community based
effort to describe interactions that arise from proteomic and other
similar studies. In total, 833 gene sets were included in the
analyses, collectively referred to as knowledge-driven pathways.
We constructed two positive control gene sets using previously
known CAD candidate genes. The first positive control gene set
was based on the GWAS Catalog [20]. SNPs with P,5.0610
28
for the traits ‘Coronary heart disease’, ‘Coronary artery calcifica-
tion’ and ‘Myocardial infarction’ were collected from the catalog,
and the reported genes for these loci were included in the control
set. Another positive control was formed from the CAD candidate
genes curated in the CADgene database [21].
Data-driven modules of co-expressed genes
Consistent expression patterns among specific sets of genes were
investigated in previous studies to define co-regulated gene sets,
commonly referred to as co-expression network modules. These
modules can be considered data-driven ‘‘pathways’’ of gene
regulation that typically operate upstream of the classical pathways
of chemical signaling and enzymatic action. We utilized co-
expression modules constructed using the weighted Gene Co-
expression Network Analysis [13] from ,10 human and mouse
studies that involved multiple CAD-related tissues (details and
references in Table S9). Human modules were obtained from
HAEC, adipose tissue, blood, and liver. Mouse modules were
obtained from adipose tissue, liver, muscle, brain, heart, islet cells
and kidney. A total of 2706 co-expression modules representing
data-defined functional units of genes were used in this study.
Expression SNPs (eSNPs) from human expression
quantitative trait loci (eQTL) studies
Human eQTL studies are analogous to GWAS of quantitative
traits, except that the traits are tissue-specific gene expression levels
rather than biomarkers or clinical measures. eQTL studies
constitute an important source of empirically supported mappings
from a genetic variant (eSNP) to its gene target and these
mappings can be reversed to convert a gene set back into the
respective eSNP set for direct testing of disease associations in
GWAS. The human eSNP data used in this study were collected
previously from adipose tissue, liver, HAEC, blood, fibroblasts,
lymphoblasts, and monocytes (details and references in Table S9).
Both cis-eSNPs (within 1 Mb distance from gene region) and
trans-eSNPs (beyond 1 Mb from gene region) at false discover rate
,10% were included. We chose adipose tissue, liver, blood and
HAEC for tissue-specific analyses due to their direct relevance to
CAD and relative abundance of eSNPs, while all eSNP resources
were pooled into a tissue-independent set denoted as ‘All eSNPs’,
yielding five sets of gene-eSNP mapping for each gene set.
We observed a high degree of linkage disequilibrium (LD)
between eSNPs. If left uncorrected, redundant eSNPs can inflate
the disease association scores of a pathway or gene network and
increase the number of false positives. For this reason, we devised
an algorithm to remove eSNPs in LD while preferentially keeping
those with a strong statistical association with gene expression
(Text S1). The preferential treatment based on these expression
association P-values was motivated by previous observations that
disease loci are enriched among eSNPs [36,65].
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sample sizes and study designs. Simply comparing the raw
expression association P-values in the LD pruning algorithm
could potentially skew the selection according to the study
characteristics rather than biological relevance. Therefore, we
ranked the expression association P-values and scaled the ranks to
the interval between 0 and 1 within the study-specific eSNP
dataset before pooling the studies and applying the LD pruning
algorithm.
The reduction in the number of accepted eSNPs after LD
pruning was smooth over a wide range of LD thresholds (Figure
S3). We chose a moderate LD cutoff (R
2,0.7) that lead to the
rejection of approximately 50% of eSNPs. This cutoff was chosen
because it preserves statistical power while removing eSNPs in
high LD. We used the LD structure of the CEU HapMap
population [66] for the eSNP pruning given our CAD GWAS
included only subjects of white/European descent.
SNP set enrichment analysis (SSEA)
We applied a modified SSEA to identify gene sets associated
with CAD [36,37] (Figure 1A). We collected gene sets from
knowledge-based pathway databases, or defined them according to
data-driven co-expression network modules (Figure 1A, left). We
also determined the specific sets of eSNPs that perturb the
expression of the member genes in each gene set based on the
tissue-specific eSNP sets described above (Figure 1A, middle). We
retrieved the CAD association P-values for the eSNPs from the
CAD GWAS (Stage 1, Stage 2, Stage 1+2, separately), compared
the P-values against the random expectation, and summarized the
observed difference as a single enrichment score, as detailed below
(Figure 1A, right).
Importantly, the study involved two levels of P-values. The first
level of P-values for each SNP in the GWAS was calculated
according to the genotypes of the participating individuals in
relation to their CAD phenotype. For our purposes, these trait
association P-values represent the statistical strengths of CAD
associations, and produce the ranking of eSNPs according to their
relevance to CAD. It has been previously observed that eSNPs are
enriched for disease associations [36,65]. Therefore, simply using
eSNPs to determine pathway signals typically leads to false
positives. In our study, we first removed SNPs that were not
eSNPs, and used the remaining pool of eSNPs as the null
background for subsequent enrichment tests. For instance, the
background for adipose tissue comprised all the 59,979 non-
redundant adipose eSNPs. This procedure was adopted for each
tissue-specific eSNP set separately.
The gene set enrichment P-values represent the second level of
P-values which reflect the degree of enrichment of high ranking
disease-associated eSNPs within a given gene set as compared to
the null distribution of randomly expected uniform distribution of
all ranks. The enrichment of CAD association signals for each
gene set (pathway or co-expression module) was estimated by the
Kolmogorov-Smirnov (K-S) test and Fisher’s exact test. The K-S
test takes into account the total deviation of the observed ranks
from the expectation and is therefore sensitive to a large number of
weak GWAS signals. The Fisher’s exact test detects if the top 5%
of eSNPs based on their CAD association strength is over-
represented among the eSNPs representing a gene set of interest
(sensitive to a few strong signals). The final enrichment score was
defined as the mean 2log10 of K-S and Fisher P-values.
False discovery rates (FDR) were estimated by randomly
permuting the CAD association P-values of the background
eSNPs while keeping all other data structures intact. For a single
permutation, FDR was estimated as the ratio between the number
of permuted gene sets that exceeded a given enrichment score, and
the observed number of gene sets that actually exceeded the score
threshold. The final FDR was averaged over 1000 permutations
for each tissue-specific eSNP set separately. Gene sets that satisfied
FDR,20% in both Stage 1 and Stage 2 GWAS sets, and
FDR,5% in the combined Stage 1+2 were considered statistically
significant. As Stage 1 and Stage 2 were independent, the request
for simultaneous satisfaction for these FDR cutoffs ensured the
overall FDR to be ,5%. SSEA was performed in R.
Gene set overlaps and construction of supersets
A substantial number of gene sets overlapped based on their
shared member genes, given that similar functional units of genes
could be captured by the pathway databases and gene expression
studies used in the study. To reduce the redundancy of the dataset,
we collapsed overlapping CAD-associated gene sets into non-
overlapping ‘‘supersets’’ (Figure 1B). When multiple gene sets are
merged, the size of the resulting superset can grow very large. For
this reason, we included only the core genes (that were shared with
most of the constituent gene sets) in the final supersets.
For two gene sets A and B with different numbers of member
genes, two overlap ratios were calculated: the proportion of genes
in A that were also in B (rAB), and the proportion of genes in B that
were also in A (rBA). We chose the formula r=(r AB6rBA)
0.5 to
describe the degree of overlap. Importantly, r is small whenever
the sizes of A and B are substantially different, which discourages
the merging of nested gene sets. We also required that Fisher’s
exact test for the number of shared genes was statistically
significant (P,0.05 after Bonferroni correction).
We employed hierarchical clustering to define blocks of
overlapping gene sets. First, the overlap matrix of the CAD-
associated gene sets was estimated and all non-significant elements
were set to zero. The overlaps were then converted to distances
d=(1-r). Clusters of overlapping gene sets were identified by the
hclust() function in the R programming environment with a static
cutoff at zero overlap. In the last step, the gene sets within clusters
were merged and trimmed into supersets. The above procedure
was repeated two times to reduce the maximum observed overlap
below 20% between any two resulting supersets.
A size limit of 200 genes was chosen to trim the raw supersets
down to the core genes that were shared across overlapping gene
sets. This choice of optimal size was motivated by earlier SSEA
analyses [37]. The least shared genes were successively removed
until the next removal would have reduced the superset size below
the 200-gene limit. Overlap ratios were re-calculated between the
trimmed supersets before the next round of hierarchical clustering.
The functional categorization of each superset was based on the
known pathways from the Gene Ontology and KEGG databases.
We evaluated the over-representation of a functional category
within the member genes of a superset with the Fisher’s exact test.
Significant functional categories (P,0.05 after Bonferroni correc-
tion) were used to annotate the functionality of each superset. If no
significant annotation could be found, we labeled the superset as
‘Unknown’. A second round of SSEA was performed for the
merged supersets to confirm that they captured the features of the
pre-merged gene sets. Significance was determined at SSEA P,
0.05 after Bonferroni-correction for the number of all original
gene sets (n=3539, not the number of supersets after merging) to
ensure stringency.
Bayesian network models of causal gene-gene
interactions
The above SSEA analysis is able to identify a gene set that is
likely to contain disease-causing genetic variation. To pinpoint the
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models of gene-gene interactions that take into account both the
genotypes that affect gene expression (causal direction known), and
the statistical relationships between gene expression levels (causal
direction uncertain), using the established method by Zhu et al.
[29,67]. Bayesian network models from human and mouse studies
were constructed based on genetics and gene expression data
generated from multiple tissues from multiple previously published
studies, each involving hundreds of individuals (details and
references in Table S9). Human networks were obtained from
adipose tissue, blood, and liver. Mouse networks were obtained
from adipose tissue, liver, muscle, brain, and kidney.
Bayesian networks are directed acyclic graphs in which the
edges of the graph are defined by conditional probabilities that
characterize the distribution of states of each gene given the state
of its parents [68]. The network topology defines a partitioned
joint probability distribution over all genes in a network. The
likelihood of a Bayesian network model given observed genomic
data is determined using Bayes formula. For each dataset, 1000
Bayesian networks, each using different random seeds, were
reconstructed using Monte Carlo Markov Chain simulation [69].
Bayesian Information Criteria was used to determine the model
with the best fit for each network. From the resulting set of 1000
networks, edges that appeared in greater than 30% of the networks
were used to define a consensus network for a given dataset. To
infer causal directions between genes in a network, genetic
information was used as priors by allowing genes with cis-eSNPs to
be parent nodes of genes without cis-eSNPs and preventing genes
without cis-eSNPs to be parents of genes with cis-eSNPs [70].
Bayesian network provides a natural framework for integrating
diverse data and reconstruct biological causal networks.
Key driver analysis (KDA)
We used the key driver analysis (KDA) to determine the key
regulatory genes of the CAD-associated gene supersets [12,28,29].
We defined a key driver as a gene that is connected to a large
number of genes from a CAD-associated superset, compared to
the expected number for a randomly selected gene within a
Bayesian causal network. The basic idea of KDA is depicted in
Figure 1C. First, one needs a network topology that defines links
between pairs of genes. In this study, we used tissue-specific
Bayesian networks that were constructed from large-scale genetic
and genomic datasets from multiple previously published studies as
described above. Second, a disease-related gene set is needed. In
our study, this comes from the CAD-associated gene supersets (call
it Gene Set S). We then tag each of the member genes in the Gene
Set S within the network, as shown by the colored nodes in
Figure 1C. For a gene in the network (call it Gene A), we then ask
the following question: How many of Gene A’s neighbors are
members in the Gene Set S? If the proportion of member genes is
higher than what could be expected for a random gene set, we
define Gene A as a key driver for Gene Set S. The statistical
significance of a key driver for a given CAD superset in a
particular Bayesian network is determined by Fisher’s exact test
which assesses the enrichment of CAD genes in the candidate
key driver’s network neighborhood. Bonferroni-corrected p,
0.05 was used to determine key drivers. As multiple networks
were available for a number of tissues, we used two criteria to
prioritize the five most important key driver genes. Firstly, we
counted how many times a gene was a key driver in multiple
networks (denoted as N). The consistency across networks was
expressed as (N - 0.99) to strongly favor key genes that could be
identified in at least two networks. The second criterion was
based on the statistical significance of the key driver. In
particular, the significance value was calculated as mean(-log
P), where P denotes the KDA significance P-values from each of
the networks. The final ranking of genes was based on the
product of the consistency and significance criteria. KDA was
performed using R.
Small interfering RNA (siRNA) experiments to test the
regulatory role of candidate key driver genes
To test whether perturbing key drivers identified in our study
indeed result in perturbations of CAD gene networks, we used
siRNAs to knockdown the expression of novel key drivers in
HAECs. HAECs were grown to 80% confluency on 0.1% gelatin
coated culture plates in MCDB-131 complete medium (VEC
technologies). Cells were transfected with siRNAs against each
candidate key driver gene under investigation and a negative
control (Cat. No. 1027280) at a final concentration of 40 nM
with Lipofectamine 2000 reagent for 4 hours in Opti-MEM
medium (Invitrogen). Three HAEC lines from different donors
were used as biological replicates for each siRNA. Media was
replaced with MCDB-131 and cells were lysed for RNA
isolation after 24 hours. Whole transcriptome expression was
assessed with Illumina HumanHT-12 v4 Expression BeadChip.
We identified the differential expression of genes between cells
transfected with the siRNAs targeting the candidate genes and
t h ec o n t r o ls i R N Au s i n gt h el i m m ap a c k a g ei nR( 2 . 1 4 . 0 ) .
Overlap between the differentially expressed genes in siRNA
experiments and a CAD network of interest was assessed using
Fisher’s exact test.
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